- Coromandel’s 1Q net income was 3.11 billion rupees, missing the estimate of 3.87 billion rupees.
- Net income fell by 37% year-over-year.
- Revenue for the quarter was 47.3 billion rupees, slightly below the 47.76 billion rupees estimate.
- Revenue decreased by 17% compared to the same period last year.
- Total costs stood at 43.5 billion rupees, down by 14% year-over-year.
- Raw material costs were 29.8 billion rupees, significantly lower than the 37.67 billion rupees estimate.
- Raw material costs dropped by 25% year-over-year.
- Finance costs increased by 42% year-over-year to 574.2 million rupees, higher than the 412.1 million rupees estimate.
- Analyst ratings: 9 buy, 1 hold, and 2 sell recommendations.
A look at Coromandel International Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Coromandel International Ltd., a manufacturer of fertilizers and pesticides, seems poised for a promising long-term future, as indicated by its Smartkarma Smart Scores. With solid ratings across the board, including above-average scores in Resilience and Momentum, the company appears to have a strong foundation for sustained growth and stability. The balanced ratings in Value, Dividend, and Growth further suggest a well-rounded performance outlook for Coromandel International.
Coromandel International‘s focus on manufacturing both chemical and organic fertilizers, along with a range of other agricultural products like insecticides and plant growth enhancers, positions the company well in the agricultural industry. With a blend of resilience, momentum, and moderate scores in other key areas, Coromandel International appears to be on track to continue its path of steady growth and development in the coming years.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
